Back to GetFilings.com




UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________

FORM 10-Q

[X]    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended November 30, 2004

OR

[   ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For The Transition Period From _________ To ________

Commission File Number 0-16006

COGNOS INCORPORATED
(Exact Name Of Registrant As Specified In Its Charter)

CANADA 98-0119485
(State Or Other Jurisdiction Of (IRS Employer Identification No.)
Incorporation Or Organization)

3755 Riverside Drive,
P.O. Box 9707, Station T,
Ottawa, Ontario, Canada

(Address Of Principal Executive Offices)
K1G 4K9
(Zip Code)

(613) 738-1440
(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES   X       NO         

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
YES   X      NO          

The number of shares outstanding of the registrant’s only class of Common Stock as of December 15, 2004, was 91,003,345.



COGNOS INCORPORATED

INDEX

 
PAGE
 
PART I - FINANCIAL INFORMATION
 
Item 1.   Unaudited Consolidated Financial Statements      
 
  Consolidated Statements of Income for the three and nine months ended November 30, 2004 and November 30, 2003   3  
 
  Consolidated Balance Sheets as of November 30, 2004 and February 29, 2004   4  
 
  Consolidated Statements of Cash Flows for the three and nine months ended November 30, 2004 and November 30, 2003  5  
 
  Condensed Notes to the Consolidated Financial Statements   6  
 
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations  19  
 
Item 3.   Quantitative and Qualitative Disclosure about Market Risk  49  
 
Item 4.  Controls and Procedures  50  
 
 
PART II - OTHER INFORMATION
 
Item 1.  Legal Proceedings  51  
 
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds  51  
 
Item 6.  Exhibits  52  
 
Signature    53  

2


PART I — FINANCIAL INFORMATION

Item 1.   Unaudited Consolidated Financial Statements

COGNOS INCORPORATED
CONSOLIDATED STATEMENTS OF INCOME
(US$000s except share amounts, U.S. GAAP)
(Unaudited)

     Three months ended
November 30,
  Nine months ended
November 30,
 

     2004   2003   2004   2003  

Revenue 
   Product license   $   91,580   $   72,551   $ 233,012   $ 192,586  
   Product support  81,031   68,676   231,974   198,965  
   Services  37,755   31,000   104,219   89,420  

Total revenue  210,366   172,227   569,205   480,971  

Cost of revenue 
   Cost of product license  578   1,121   1,745   3,338  
   Cost of product support  8,508   7,051   22,757   20,793  
   Cost of services  28,574   22,924   81,506   65,286  

Total cost of revenue  37,660   31,096   106,008   89,417  

Gross margin  172,706   141,131   463,197   391,554  

Operating expenses 
   Selling, general, and administrative  102,206   85,959   282,945   247,692  
   Research and development  26,987   22,265   76,694   67,273  
   Amortization of intangible assets  1,672   2,116   4,413   6,212  

Total operating expenses  130,865   110,340   364,052   321,177  

Operating income  41,841   30,791   99,145   70,377  
Interest expense  (22 ) (552 ) (101 ) (877 )
Interest income  1,909   975   5,094   3,562  

Income before taxes  43,728   31,214   104,138   73,062  
Income tax provision  9,183   6,966   21,869   18,265  

Net income  $   34,545   $   24,248   $   82,269   $   54,797  

Net income per share 
   Basic  $0.38   $0.27   $0.91   $0.61  

   Diluted  $0.37   $0.26   $0.89   $0.60  

Weighted average number of shares (000s) 
   Basic  90,621   89,692   90,364   89,133  

   Diluted  93,235   92,614   92,925   91,779  

(See accompanying notes)

3


COGNOS INCORPORATED
CONSOLIDATED BALANCE SHEETS
(US$000s, U.S. GAAP)

  November 30,
2004
February 29,
2004

Assets   (Unaudited)   (Note 1)  
Current assets      
  Cash and cash equivalents  $ 313,937   $ 224,830  
  Short-term investments  125,430   163,411  
  Accounts receivable  142,763   152,859  
  Prepaid expenses and other current assets  14,832   16,668  
  Deferred tax assets  1,656   2,445  

   598,618   560,213  
Fixed assets  73,622   71,292  
Intangible assets  28,846   23,643  
Goodwill  222,883   172,323  

   $ 923,969   $ 827,471  

Liabilities  
Current liabilities 
  Accounts payable  $   33,415   $   30,698  
  Accrued charges  30,524   25,483  
  Salaries, commissions, and related items  68,576   59,903  
  Income taxes payable  13,809   5,875  
  Deferred revenue  153,137   178,752  

   299,461   300,711  
Deferred income taxes  23,357   18,098  

   322,818   318,809  

Stockholders’ Equity  
Capital stock 
  Common shares and additional paid-in capital 
     (November 30, 2004 – 90,825,717; February 29, 2004 – 89,902,895)  237,540   206,499  
  Treasury shares 
     (November 30, 2004 – 46,375; February 29, 2004 – 43,500)  (1,199 ) (1,065 )
  Deferred stock-based compensation  (496 ) (730 )
Retained earnings  361,707   305,399  
Accumulated other comprehensive income (loss)  3,599   (1,441 )

   601,151   508,662  

   $ 923,969   $ 827,471  

(See accompanying notes)

4


COGNOS INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(US$000s, U.S. GAAP)
(Unaudited)

     Three months ended November 30,   Nine months ended November 30,  

     2004   2003   2004   2003  

Cash flows from operating activities          
   Net income  $   34,545   $   24,248   $   82,269   $   54,797  
   Non-cash items 
     Depreciation and amortization  7,658   7,252   20,660   21,718  
     Amortization of deferred stock-based compensation  109   215   514   605  
     Amortization of other deferred compensation  --   44   7   168  
     Deferred income taxes  (1,329 ) 1,227   972   5,280  
     Loss on disposal of fixed assets  89   76   213   539  

   41,072   33,062   104,635   83,107  
Change in non-cash working capital 
  Decrease (increase) in accounts receivable  (14,405 ) (5,716 ) 22,056   26,181  
  Decrease (increase) in prepaid expenses and other current assets  3,980   2,327   4,151   (1,533 )
  Increase (decrease) in accounts payable  3,864   837   (3,121 ) (9,941 )
  Decrease in accrued charges  (2,346 ) (4,610 ) (4,243 ) (11,682 )
  Increase (decrease) in salaries, commissions, and related items  8,580   6,647   1,305   (7,141 )
  Increase in income taxes payable  7,630   3,967   7,586   5,126  
  Decrease in deferred revenue  (10,051 ) (7,314 ) (31,542 ) (22,665 )

Net cash provided by operating activities  38,324   29,200   100,827   61,452  

Cash flows from investing activities  
   Maturity of short-term investments  75,897   88,663   320,571   205,473  
   Purchase of short-term investments  (125,460 ) (144,406 ) (282,421 ) (277,445 )
   Additions to fixed assets  (4,261 ) (5,784 ) (11,971 ) (17,282 )
   Additions to intangible assets  (242 ) (381 ) (771 ) (1,067 )
   Acquisition costs, net of cash and cash equivalents  (49,706 ) (254 ) (49,706 ) (484 )

Net cash used in investing activities  (103,772 ) (62,162 ) (24,298 ) (90,805 )

Cash flows from financing activities  
   Issue of common shares  13,548   8,896   32,820   27,005  
   Purchase of treasury shares  --   --   (335 ) (564 )
   Repurchase of shares  (7,965 ) --   (27,820 ) --  
   Decrease in long-term debt and long-term liabilities  --   --   --   (1,697 )

Net cash provided by financing activities  5,583   8,896   4,665   24,744  

Effect of exchange rate changes on cash  9,020   4,111   7,913   8,248  

Net increase (decrease) in cash and cash equivalents  (50,845 ) (19,955 ) 89,107   3,639  
Cash and cash equivalents, beginning of period  364,782   186,182   224,830   162,588  

Cash and cash equivalents, end of period  313,937   166,227   313,937   166,227  
Short-term investments, end of period  125,430   154,668   125,430   154,668  

Cash, cash equivalents, and short-term investments, end of period  $ 439,367   $ 320,895   $ 439,367   $ 320,895  

(See accompanying notes)

5


COGNOS INCORPORATED
CONDENSED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(All amounts in U.S. dollars, unless otherwise stated)
(In accordance with U.S. GAAP)

1.   Basis of Presentation

  The accompanying unaudited consolidated financial statements have been prepared by the Corporation in United States (“U.S.”) dollars and in accordance with generally accepted accounting principles (“GAAP”) in the U.S. with respect to interim financial statements, applied on a consistent basis. The consolidated balance sheet as at February 29, 2004 has been extracted from the audited consolidated financial statements at that date. These consolidated financial statements do not include all of the information and footnotes required for compliance with GAAP in the U.S. for annual financial statements. These unaudited condensed notes to the consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Corporation’s Annual Report on Form 10-K for the fiscal year ended February 29, 2004.

  The preparation of these unaudited consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. In the opinion of management, these unaudited consolidated financial statements reflect all adjustments (which include only normal, recurring adjustments) necessary to state fairly the results for the periods presented. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.

  All information is presented in U.S. dollars, unless otherwise stated. Consolidated financial statements prepared in accordance with Canadian GAAP, in U.S. dollars, are made available to all shareholders, and filed with various regulatory authorities.

2.   Revenue Recognition

  The Corporation recognizes revenue in accordance with Statement of Position (“SOP”) 97-2, Software Revenue Recognition, issued by the American Institute of Certified Public Accountants.

  Substantially all of the Corporation’s product license revenue is earned from licenses of off-the-shelf software requiring no customization. Revenue from these licenses is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectibility is probable. If a license includes the right to return the product for refund or credit, revenue is deferred, until the right of return lapses.

6


COGNOS INCORPORATED
CONDENSED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(All amounts in U.S. dollars, unless otherwise stated)
(In accordance with U.S. GAAP)

  Revenue from product support contracts is recognized ratably over the life of the contract. Incremental costs directly attributable to the acquisition of product support contracts, and that would not have been incurred but for the acquisition of that contract, are deferred and expensed in the period the related revenue is recognized. These costs include commissions payable on sales of support contracts.

  Services revenue from education, consulting, and other services is recognized at the time such services are rendered. Many of the Corporation’s sales include both software and services. Where the service is (1) not essential to the functionality of any other element of the transaction and (2) stated separately such that the total price of the arrangement is expected to vary as a result of the inclusion or exclusion of the service, the software element is accounted for separately from the service element. Where these two criteria are not met, the entire arrangement is accounted for using the percentage of completion method in accordance with SOP 81-1, Accounting for Performance of Construction Type and Certain Production Type Contracts.

  For contracts with multiple obligations (e.g., delivered and undelivered products, support obligations, education, consulting, and other services), the Corporation allocates revenue to each element of the contract based on vendor specific objective evidence (“VSOE”) of the fair value of the element. VSOE of fair value is assigned using the residual method as outlined in SOP 98-9, Modification of SOP 97-2, Software Revenue Recognition, With Respect to Certain Transactions. VSOE is the renewal rate for product support elements of a contract and, for service elements, is the normal pricing and discounting practices for those products when they are sold separately; the residual is then assigned to the license element of the contract.

3.    Stock Based Compensation

  The Corporation applies Accounting Principles Board Opinion 25, Accounting for Stock Issued to Employees (“APB 25”) in accounting for its stock option, stock purchase, and restricted share unit plans. Where the exercise price of stock options is equal to the market price of the stock on the trading day preceding the date of grant, no compensation cost has been recognized in the financial statements for its stock option and stock purchase plans. However, for certain options assumed on the acquisition of Adaytum, Inc. (“Adaytum”), under purchase accounting methodology, compensation cost has been recognized in the financial statements. For restricted share units, the fair value of each unit is calculated at the date of grant. Compensation cost relating to the restricted share unit plan is recognized in the financial statements over the vesting period.

7


COGNOS INCORPORATED
CONDENSED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(All amounts in U.S. dollars, unless otherwise stated)
(In accordance with U.S. GAAP)

  If the fair values of the options granted had been recognized as compensation expense on a straight-line basis over the vesting period of the grant, stock-based compensation costs would have reduced net income, basic net income per share and diluted net income per share as indicated in the table below (000s, except per share amounts):

       Three months ended
November 30,
  Nine months ended
November 30
 
 
       2004   2003   2004   2003  
 
  Net income:          
      As reported  $34,545   $ 24,248  $82,269   $ 54,797  
      Add: Stock-based employee compensation included above   109   215  514   605  
      Less: Stock-based employee compensation using fair value 
          based method  (4,518 (5,435 (11,355 (17,498 )
 
      Pro forma   $ 30,136   $ 19,028   $ 71,428   $ 37,904  
 
  Basic net income per share:  
      As reported  $0.38   $0.27  $0.91   $0.61  
      Add: Stock-based employee compensation included above   --   --  0.01   0.01  
      Less: Stock-based employee compensation using fair value
        based method
  (0.05 (0.06 (0.13 (0.19
 
      Pro forma  $0.33   $0.21  $0.79   $0.43  
 
  Diluted net income per share:  
      As reported  $0.37   $0.26  $0.89   $0.60  
      Add: Stock-based employee compensation included above   --   --  0.01   --  
      Less: Stock-based employee compensation using fair value
        based method
  (0.05 (0.05 (0.13 (0.19
 
      Pro forma  $0.32   $0.21  $0.77   $0.41  
 
  Weighted average number of shares:  
      Basic  90,621   89,692  90,364   89,133  
 
      Diluted  93,235   92,614  92,925   91,779  
 

8